ESSA Pharma Inc. filings document the company's completed plan of arrangement, shareholder approval process, capital-structure treatment of common shares, options and warrants, and subsequent Form 25 removal of its common stock from Nasdaq listing and Section 12(b) registration. Form 8-K reports cover material agreements, votes of securityholders, acquisition or disposition completion, governance matters, risk factors, clinical or regulatory disclosures, and operating and financial results.
ESSA Pharma Inc. filed a Post-Effective Amendment to its Form S-3 to withdraw and remove from registration any unissued and unsold securities previously registered for up to $200,000,000. This follows the completion of a business combination in which Xeno Acquisition Corp. acquired all outstanding common shares on October 9, 2025.
Shareholders received an initial cash distribution of $1.6910318 per share prior to closing and approximately $0.1242 per share at closing, plus one non-transferable CVR per share with the right to receive up to approximately $0.14 per CVR. The potential CVR pool totals up to $6.7 million, contingent on specified outcomes. As a result of the transaction, ESSA terminated all offerings under the registration and ended the effectiveness of the registration statement.
ESSA Pharma (EPIX) director reports merger-related share disposition. A Form 4 shows the reporting person disposed of 2,881 common shares on 10/09/2025 in connection with a completed business combination. All issued and outstanding ESSA Pharma shares were acquired by Xeno Acquisition Corp. for approximately US$0.12 per share plus one contingent value right (CVR) per share.
Each CVR entitles its holder to receive up to approximately US$0.14 per CVR, payable within specified periods following closing. After the transaction, the reporting person beneficially owned 0 shares.
ESSA Pharma (EPIX) reported an insider Form 4 tied to its merger close. On October 9, 2025, all common shares were acquired by Xeno Acquisition Corp. under a Business Combination Agreement.
The reporting person disposed of 14,299 common shares, reducing beneficial ownership to zero. Holders received approximately $0.12 in cash per share and one contingent value right (CVR) per share, entitling them to receive up to approximately $0.14 per CVR within specified periods following closing.
ESSA Pharma (EPIX) reported an insider transaction tied to its acquisition. On October 9, 2025, a director disposed of 30,002 common shares, reflecting the closing of a business combination in which all outstanding shares were acquired. Holders received approximately US$0.12 in cash per share plus one contingent value right (CVR) per share.
The CVR entitles the holder to receive up to approximately US$0.14 per CVR, payable within specified periods following the close. Following the transaction, the reporting person held 0 shares directly.
ESSA Pharma (EPIX) disclosed a Form 4 reflecting the completion of its sale on October 9, 2025. A reporting director disposed of 43,240 common shares, reducing beneficial ownership to 0 shares following the transaction.
Under the Business Combination Agreement among ESSA Pharma, XenoTherapeutics, Inc., Xeno Acquisition Corp., and XOMA Royalty Corporation, all issued and outstanding common shares were acquired for US$0.12 per share in cash plus one contingent value right (CVR) per share. Each CVR entitles the holder to receive up to approximately US$0.14, payable within specified periods after closing.
ESSA Pharma (EPIX) reported an insider transaction tied to its change of control. A director filed a Form 4 showing the disposition of 784,404 common shares on October 9, 2025, coinciding with the closing of a business combination.
According to the filing, Xeno Acquisition Corp. acquired all issued and outstanding ESSA common shares for approximately US$0.12 per share in cash plus one contingent value right (CVR) per share entitling holders to receive up to approximately US$0.14 per CVR within specified periods following closing.
ESSA Pharma (EPIX) reported an insider transaction tied to its completed business combination. The company’s Chief Financial Officer disposed of 33,343 common shares on October 9, 2025, as all outstanding shares were acquired by Xeno Acquisition Corp. pursuant to the Business Combination Agreement.
Holders received approximately US$0.12 per share in cash plus one contingent value right (CVR) per share, which entitles the holder to receive up to approximately US$0.14 per CVR within specified periods after closing. Following the transaction, the reporting person beneficially owned 0 shares.
ESSA Pharma (EPIX) reported an insider transaction: President and CEO David Parkinson, also a director, disposed of 65,675 common shares on October 9, 2025. The transaction occurred in connection with a business combination under which the purchaser acquired all issued and outstanding common shares for approximately US$0.12 per share plus one CVR per share entitling holders to receive up to approximately US$0.14 per CVR.
Following the transaction, the filing lists 0 shares beneficially owned.
ESSA Pharma Inc. (EPIX) insiders affiliated with Biotechnology Value Fund entities reported share dispositions tied to the company’s merger. On 10/09/2025, the transaction was coded “U,” indicating a corporate action. Reported lines show dispositions of 6,194,145 shares, 4,726,743 shares, and 560,797 shares, with 0 shares beneficially owned afterward for each line.
Per the terms, holders received $0.124231 in cash per share and one contingent value right (CVR) per share for potential cash payments of up to approximately $0.14 per share; this excludes approximately $1.69 per share previously distributed. The filing notes the arrangement under British Columbia law and identifies XenoTherapeutics, Inc. as the parent entity in the acquisition structure.